Studies treatment patterns and tumor DNA testing in advanced prostate cancer
Observes treatment choices and tumor DNA testing in adults with advanced prostate cancer.
Plain-language title generated from the registry record
Registry title: Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration
Key facts
- Where
- Arkhangelsk, Barnaul, Chelyabinsk, Irkutsk, Kazan', Krasnodar, Krasnoyarsk, Moscow, Murmansk, Nal'chik, Nizhny Novgorod, Obninsk, Omsk, Pskov, Saint Petersburg, Saransk, Sochi, Syktyvkar, Tomsk, Tver', Tyumen, Ufa, Velikiy Novgorod, and Yekaterinburg, RussiaSee the 24 sites
Where in Russia
- ArkhangelskArkhangelsk, RussiaTaking people
- BarnaulBarnaul, RussiaTaking people
- ChelyabinskChelyabinsk, RussiaTaking people
- IrkutskIrkutsk, RussiaTaking people
- Kazan'Kazan', RussiaNot yet recruiting
- KrasnodarKrasnodar, RussiaTaking people
- KrasnoyarskKrasnoyarsk, RussiaTaking people
- MoscowMoscow, RussiaTaking people
- MurmanskMurmansk, RussiaNot yet recruiting
- Nal'chikNal'chik, RussiaTaking people
- Nizhny NovgorodNizhny Novgorod, RussiaTaking people
- ObninskObninsk, RussiaTaking people
- OmskOmsk, RussiaNo longer taking part
- PskovPskov, RussiaNot yet recruiting
- Saint PetersburgSaint Petersburg, RussiaNot yet recruiting
- SaranskSaransk, RussiaNot yet recruiting
- SochiSochi, RussiaNo longer taking part
- SyktyvkarSyktyvkar, RussiaNot yet recruiting
- TomskTomsk, RussiaNo longer taking part
- Tver'Tver', RussiaNo longer taking part
- TyumenTyumen, RussiaTaking people
- UfaUfa, RussiaTaking people
- Velikiy NovgorodVelikiy Novgorod, RussiaNot yet recruiting
- YekaterinburgYekaterinburg, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07052578
- Record updated
- 22 October 2026
- Original description
A multicentre observational study on treatment patterns and ctDNA HRR evaluation in aggressive high-volume metastatic hormone-sensitive prostate cancer in Russian FederationRead full original descriptionShow less
A Multicentre Observational Study on Treatment Patterns and ctDNA HRR Evaluation in Aggressive High-volume Metastatic Hormone-sensitive Prostate Cancer in Russian Federation
A multicentre observational study on treatment patterns and ctDNA HRR evaluation in aggressive high-volume metastatic hormone-sensitive prostate cancer in Russian Federation
Inclusion: Male patients aged ≥ 18 years old; Signed ICF, including consent for blood samples ctDNA and ctDNA-based HRRm testing; Metastatic hormone-sensitive prostate cancer (mHSPC) (de novo or progressed from earlier stages); High-aggressive disease (Gleason 8-10); High-volume disease (according to CHAARTED trial criteria: presence of 4 and more (≥4) bone metastases (including at least one (≥1) outside the vertebral column/pelvis) and/or 1 and more (≥1) visceral metastasis); Availability of source medical documentation; Known HRRm status based on routine tumour sample analysis.
Exclusion: Participation in any interventional trial since the mPC diagnosis; Progression to mCRPC.